BSEM BioStem Technologies Inc

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program

Program has honored more than 500 members of the military since its inception

Sponsorship honors both local military veterans and healthcare professionals

POMPANO BEACH, Fla., Oct. 02, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, and the , announced today that they will celebrate the 13th season of the “” program throughout the upcoming 2025-26 NHL season with BioStem Technologies Inc. as the new sponsoring partner. Through the support of BioStem, the club will continue its special tradition of introducing and highlighting the important contributions of military veterans to the U.S. during all home games.

“As one of the MedTech industry anchors in South Florida, BioStem is proud to expand our partnership with the Florida Panthers as the sponsor of the ‘Heroes Among Us’ program to recognize and honor those whose military contributions have made a lasting difference to our country," said Jason Matuszewski, Chairman and CEO of BioStem Technologies.  “This sponsorship is an extension of our ongoing recognition of the sacrifices that our military members make, personified by our co-founder, Andrew Van Vurst, who is a veteran of the U.S. Marine Corps.”

Mr. Matuszewski continued, "We are also deeply honored to continue supporting the Panthers’ ‘Seats for Service’ program, which creates meaningful game-day experiences for veterans and their families. Together, these initiatives reflect our shared mission of giving back to those who have served, while also aligning with the upcoming launch of our American Amnion product line, a brand dedicated to advancing wound care for the military community.”

The “Heroes Among Us” program honors one military hero at every home game with a national anthem dedication and scoreboard video highlighting his or her story. Since its creation in 2013, the “Heroes Among Us” program has honored more than 500 local veterans and active-duty service members at Panthers’ home games, including more than 125 WWII veterans, 50 Vietnam War veterans, 20 Korean War veterans, and others.

“This program continues to be one of the most impactful moments of our games, as we honor the incredible stories of local veterans and recognize their service and sacrifice to our country,” said VP of Panthers Foundation & Community Relations, John Colombo. “It’s an honor to give our fans and community the opportunity to thank and appreciate these heroes on a nightly basis and appreciate BioStem Technologies’ support of this program.”

Nominate a Veteran for the “Heroes Among Us” Program:

The South Florida community can nominate a member of the military by visiting .

BioStem to Continue Sponsorship of the “Seats for Service” Program with the Panthers:

Additionally, BioStem will continue to support the “” initiative in partnership with the Panthers. The partnership initiated during the 2024-25 season and BioStem has supported 125 seats to date. Fans can to receive four tickets to a Panthers game at Amerant Bank Arena, one parking pass, and a $50 food and beverage credit. This initiative aims to create a memorable experience for the honorees and their families at Panthers games. Fans can nominate a veteran by clicking .

Florida Panthers Foundation:

One of the four core pillars of the Florida Panthers Foundation is veterans' affairs. The Panthers are dedicated to supporting organizations that provide critical resources and services to active duty and retired military members. For more information on the Panthers Foundation, please visit .

Purchase Tickets:

The Florida Panthers are back-to-back 2024 & 2025 Stanley Cup Champions! Fans interested in purchasing a Partial Plan for the 2025-26 season can click , visit , or by calling PUCK line (954.835.PUCK). 

Join BioStem’s Distribution List & Social Media:

To follow the latest developments at BioStem, sign-up to the Company’s email distribution list , and follow us on , and .

About BioStem Technologies:

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.

For more information visit  and follow us on , and .

Contact BioStem Technologies, Inc.:

Website: 

E-Mail: 

X: 

Facebook: 

Phone: 954-380-8342

Investor Relations:

Adam Holdsworth, BioStem Director of Investor Relations

E-Mail: 

Phone: 954-854-2409

Or

Gilmartin Group:

Philip Trip Taylor, Principal

E-Mail: 

Phone: 415-937-5406



EN
02/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioStem Technologies Inc

 PRESS RELEASE

BioStem Technologies Highlights Alignment with FDA’s Openness to Bayes...

BioStem Technologies Highlights Alignment with FDA’s Openness to Bayesian Statistical Approaches in Clinical Research POMPANO BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today underscored the significance of recent remarks from U.S. Food and Drug Administration (FDA) leadership signaling openness to expanded use of Bayesian statistical methodologies in clinical trial design and analysis. FDA Commissioner, Dr. Martin Maka...

 PRESS RELEASE

BioStem Technologies Advances Entry into the Acute Wound Care Market w...

BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings’ Surgical and Wound Care Business Accelerates expansion of BioStem’s commercial organization through integration of an experienced national sales force Expands access to major GPO networks, strengthening BioStem’s position across hospital settings Barry Hassett promoted to Chief Commercial Officer Conference call scheduled for tomorrow, January 22nd at 8am ET POMPANO BEACH, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development...

 PRESS RELEASE

BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medic...

BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes Decision ensures continued patient access to VENDAJE® and VENDAJE AC® POMPANO BEACH, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today commented on the withdrawal of all seven of the Centers for Medicare & Medicaid Services’ (“CMS”) Local Coverage Determinations (“LCD”) for skin substitute grafts/cellular and tissue-based ...

 PRESS RELEASE

BioStem Technologies Products Placed on “12-Month Status Quo Period” L...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority of BioStem’s non-acute revenue, treatment for pressure ulcers, also remains unaffected by CMS LCD updates   POMPANO BEACH, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental...

 PRESS RELEASE

BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foo...

BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference Expanding its Portfolio with American Amnion to Serve the Wound Care Needs of Our Veterans POMPANO BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in placental-derived biologics for advanced wound care, today announced the launch of a new product line, American Amnion, at the Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference held in Phoenix, Arizona, on December ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch